Elcella, a supplement developed by researchers at Queen Mary University of London, entered the market in early 2024 as a purported natural alternative to injectable weight‑loss drugs such as Mounjaro. the product delivers a blend of fatty acids to the colon to trigger gut hormones that signal fullness, and early users report noticeable appetite suppression and modest weight loss.

Elcella’s 12‑week study with 51 participants shows 6 kg average loss

According to the company’s 12‑week observational trial, 51 volunteers began the regimen and 34 completed it. The report says 94% of completers experienced better appetite control, an average weight loss of 6 kg (about 13 lb), and a waist reduction of roughly 7 cm (2.76 in). These figures are presented as the primary evidence supporting the supplement’s claims.

The study was not a randomized controlled trial, and the company classifies Elcella as a food product , meaning it bypasses the rigorous drug‑approval process. Nonetheless, the results have generated buzz among consumers who cannot use GLP‑1 injections because of gallstone risk or other medical concerns.

The colon‑targeted fatty acid blend: alpha‑linolenic, lauric, capric and caprylic

Elcella’s mechanism hinges on a coated capsule that protects four specific fatty acids—alpha‑linolenic, lauric, capric and caprylic—until they reach the colon. There, L‑cells release hormones such as GLP‑1 and peptide YY (PYY), which naturally curb hunger. Researchers designed the coating to avoid absorption in the stomach and small intestine, a step that distinguishes the product from simply eating linseed or coconut oil.

While the science of gut‑derived hormones is well‑established, the efficacy of delivering them via dietary fats remains unproven at scale. As the source notes, “the idea is to trigger hunger suppression right before appetite peaks,” but long‑term hormone levels have not been measured in the trial.

Personal account: nine‑pound loss in two weeks, then a plateau

A self‑reported trialer described taking eight capsules daily (four before lunch, four before dinner) and noticing reduced cravings within days while traveling in Austria and Italy. After two weeks, the individual claimed a nine‑pound loss and no digestive side effects, attributing the change to the supplement’s colon‑focused action.

However, the same account notes that the strong appetite suppression faded after returning home, suggesting that the effect may be inconsistent or influenced by lifestyle factors. The anecdote underscores the variability that the company itself acknowledges: “the experience suggests that Elcella may work for some, but individual results vary.”

Cost of $50 per month and regulatory gray zone

Elcella is priced at roughly $50 a month and is sold online as a food supplement. because it does not require the same regulatory scrutiny as prescription drugs, consumers can purchase it without a medical prescription, raising questions about oversight, quality control, and labeling accuracy.

Health experts caution that the lack of FDA or EMA approval means the product’s safety profile is not fully vetted, especially for people with underlying gastrointestinal conditions. The source highlights that the supplement “does not require the same regulatory approval as drugs,” a point that may attract both cost‑conscious shoppers and skeptics.

Will appetite suppression persist long‑term?

One of the most pressing unanswered questions is whether the colon‑targeted hormone release can sustain appetite control beyond the initial weeks. The trial’s 12‑week duration provides limited insight into durability,and the personal account indicates a waning effect after the first fortnight.

Additionally, the study did not include a placebo group,making it difficult to separate physiological effects from behavioral changes. As the report states, “the company conducted a 12‑week observational study,” leaving the scientific community to call for more rigorous, blinded research.